Alexandra Efthymiadou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexandra Efthymiadou has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Dionisios Chrysis
Division of Endocrinology Department of Pediatrics, Medical School, University of Patras, Rio, Greece
6 shared publications - Eirini Kostopoulou
Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University Hospital of Patras, University of Patras School of Medicine, 26504 Patras, Greece
4 shared publications - Aristeidis Giannakopoulos
Department of Pediatrics, Division of Endocrinology, Medical School, University of Patras, Patras, Greece
3 shared publications Dionisios Chrysis
University of Patras Department of Medicine: Panepistemio Patron Tmema Iatrikes
3 shared publications- Maria Athanasopoulou
Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University Hospital of Patras, University of Patras School of Medicine, 26504 Patras, Greece
2 shared publications - Maria Tsanti
Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University Hospital of Patras, University of Patras School of Medicine, 26504 Patras, Greece
2 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Springer Nature in Research Square
Transient congenital hypothyroidism in a neonate with thyroid hormone resistance
Purpose To describe a rare neonatal thyroid phenotype in the setting of maternal autoimmune thyroid disease and resistance to thyroid hormone beta (RTHβ), and to highlight the diagnostic challenge posed by evolving biochemical findings in early life. Results A preterm male infant born at 33 weeks’ gestation initially presented with congenital hypothyroidism and was started on levothyroxine. During follow-up, thyroid hormone levels rose progressively despite only mildly elevated, non-suppressed TSH, prompting treatment withdrawal and further evaluation. Whole-exome sequencing identified a heterozygous pathogenic THRβ variant (c.728G > A; p.Arg243Trp), confirming RTHβ. Maternal testing revealed the same variant together with positive thyroid autoantibodies consistent with Hashimoto’s thyroiditis. The infant’s course suggested an early transient hypothyroid phase, likely mediated by maternal thyroid-blocking antibodies, followed by emergence of the biochemical thyroid hormone profile of RTHβ. Conclusions This case illustrates that neonatal thyroid status in offspring of mothers with concurrent autoimmune thyroid disease and RTHβ may change over time and may not be predicted by maternal phenotype alone. Careful serial assessment of thyroid function is essential to distinguish transient antibody-mediated hypothyroidism from inherited RTHβ, thereby guiding appropriate treatment.
- 21 July 2026
- Published by Springer Nature in Research Square
Open AccessTransient congenital hypothyroidism in a neonate with thyroid hormone resistance
Purpose To describe a rare neonatal thyroid phenotype in the setting of maternal autoimmune thyroid disease and resistance to thyroid hormone beta (RTHβ), and to highlight the diagnostic challenge posed by evolving biochemical findings in early life. Results A preterm male infant born at 33 weeks’ gestation initially presented with congenital hypothyroidism and was started on levothyroxine. During follow-up, thyroid hormone levels rose progressively despite only mildly elevated, non-suppressed TSH, prompting treatment withdrawal and further evaluation. Whole-exome sequencing identified a heterozygous pathogenic THRβ variant (c.728G > A; p.Arg243Trp), confirming RTHβ. Maternal testing revealed the same variant together with positive thyroid autoantibodies consistent with Hashimoto’s thyroiditis. The infant’s course suggested an early transient hypothyroid phase, likely mediated by maternal thyroid-blocking antibodies, followed by emergence of the biochemical thyroid hormone profile of RTHβ. Conclusions This case illustrates that neonatal thyroid status in offspring of mothers with concurrent autoimmune thyroid disease and RTHβ may change over time and may not be predicted by maternal phenotype alone. Careful serial assessment of thyroid function is essential to distinguish transient antibody-mediated hypothyroidism from inherited RTHβ, thereby guiding appropriate treatment.
- Open Access
The Impact of Insulin Pump Therapy on Glycemic Regulation in Children and Adolescents with Type 1 Diabetes Mellitus—Preliminary Data from a Single Tertiary Pediatric Center
Background/Objectives: Advanced technologies in type 1 diabetes mellitus (T1DM) management have reshaped the strategies used to achieve optimal glucose control. Continuous subcutaneous insulin infusion (CSII) and automated insulin delivery (AID) systems are effective alternatives to multiple daily injections (MDI). This study aims to evaluate glycemic regulation in children and adolescents transitioning from MDI to insulin pumps and to raise awareness among patients and their families regarding the benefits of these systems. Methods: 50 pediatric patients with T1DM (24 males, 26 females; mean age 10.76 ± 3.2 years) were evaluated. Cycle 1 established MDI metrics 3 months pre-transition. In cycle 2, patients transitioned either to an AID system (Medtronic MiniMed 780G, (Northridge, CA, USA), 78%), or a non-automated system (Omnipod DASH, 22%). Data were assessed at 3 and 6 months post-initiation. Parameters assessed were glycosylated hemoglobin (HbA1c), time in range (TIR), time above range (TAR), time below range (TBR), glucose management indicator (GMI) and coefficient of variation (CV). Results: The cohort exhibited a statistically significant increase in TIR (p = 0.0038) with mean values of 70.9% at 3 months and 73.2% at 6 months. TAR significantly reduced (p = 0.033) to 26.5% and 24.3% at 3 and 6 months, respectively. Sub-analysis in the AID group revealed a marked increase in TIR (p = 0.0001) alongside significant reductions in TAR (p = 0.0009) and GMI (p = 0.03). Conclusions: Transitioning from MDI to insulin pump therapy, particularly AID systems, leads to modest but significant improvements in specific sensor metrics (TIR, TAR) in real-world clinical practice. The consistency of these results across age groups indicates that AID systems can successfully overcome pediatric and adolescent diabetes management challenges.
Open AccessThe Impact of Insulin Pump Therapy on Glycemic Regulation in Children and Adolescents with Type 1 Diabetes Mellitus—Preliminary Data from a Single Tertiary Pediatric Center
Background/Objectives: Advanced technologies in type 1 diabetes mellitus (T1DM) management have reshaped the strategies used to achieve optimal glucose control. Continuous subcutaneous insulin infusion (CSII) and automated insulin delivery (AID) systems are effective alternatives to multiple daily injections (MDI). This study aims to evaluate glycemic regulation in children and adolescents transitioning from MDI to insulin pumps and to raise awareness among patients and their families regarding the benefits of these systems. Methods: 50 pediatric patients with T1DM (24 males, 26 females; mean age 10.76 ± 3.2 years) were evaluated. Cycle 1 established MDI metrics 3 months pre-transition. In cycle 2, patients transitioned either to an AID system (Medtronic MiniMed 780G, (Northridge, CA, USA), 78%), or a non-automated system (Omnipod DASH, 22%). Data were assessed at 3 and 6 months post-initiation. Parameters assessed were glycosylated hemoglobin (HbA1c), time in range (TIR), time above range (TAR), time below range (TBR), glucose management indicator (GMI) and coefficient of variation (CV). Results: The cohort exhibited a statistically significant increase in TIR (p = 0.0038) with mean values of 70.9% at 3 months and 73.2% at 6 months. TAR significantly reduced (p = 0.033) to 26.5% and 24.3% at 3 and 6 months, respectively. Sub-analysis in the AID group revealed a marked increase in TIR (p = 0.0001) alongside significant reductions in TAR (p = 0.0009) and GMI (p = 0.03). Conclusions: Transitioning from MDI to insulin pump therapy, particularly AID systems, leads to modest but significant improvements in specific sensor metrics (TIR, TAR) in real-world clinical practice. The consistency of these results across age groups indicates that AID systems can successfully overcome pediatric and adolescent diabetes management challenges.
- Open Access
- 24 April 2026
- Published by MDPI AG in Preprints.org
The Impact of Insulin Pump Therapy on Glycemic Regulation in Children and Adolescents with Type 1 Diabetes Mellitus
Background/Objectives: Advanced technologies in type 1 diabetes mellitus (T1DM) management have reshaped the strategies used to achieve optimal glucose control. Continuous Subcutaneous Insulin Infusion (CSII) and Automated Insulin Delivery (AID) systems are effective alternatives to multiple daily injections (MDI). This study aims to evaluate glycemic regulation in children and adolescents transitioning from MDI to in-sulin pumps and to raise awareness among patients and their families regarding the benefits of these systems. Methods: 50 pediatric patients with T1DM (24 males, 26 fe-males; mean age 10.76 ± 3.2 years) were evaluated. Cycle 1 established MDI metrics 3 months pre-transition. In cycle 2, patients transitioned either to an AID system (Medtronic MiniMed 780G, 78%), or a non-automated system (Omnipod DASH, 22%). Data were assessed at 3- and 6-months post-initiation. Parameters assessed were: Glycosylated hemoglobin (HbA1c), Time In Range (TIR), Time Above Range (TAR), Time Below Range (TBR), Glucose Management Indicator (GMI), Coefficient of Variation (CV). Results: The cohort exhibited a statistically significant increase in TIR (p=0.0038) with mean values of 70.9% at 3 months and 70.8% at 6 months. TAR significantly reduced (p=0.033) to 26.5% and 24.3% at 3 and 6 months, respectively. Sub-analysis in the AID group, revealed a marked increase in TIR (p=0.0001) alongside significant reductions in TAR (P=0.0009) and GMI (p=0.03). Conclusion: Transitioning from MDI to insulin pump therapy, particularly AID systems, is transforming the clinical landscape of T1DM management. The con-sistency of these results across age groups indicates that AID systems can successfully overcome pediatric and adolescent diabetes management challenges.
- 24 April 2026
- Published by MDPI AG in Preprints.org
Open AccessThe Impact of Insulin Pump Therapy on Glycemic Regulation in Children and Adolescents with Type 1 Diabetes Mellitus
Background/Objectives: Advanced technologies in type 1 diabetes mellitus (T1DM) management have reshaped the strategies used to achieve optimal glucose control. Continuous Subcutaneous Insulin Infusion (CSII) and Automated Insulin Delivery (AID) systems are effective alternatives to multiple daily injections (MDI). This study aims to evaluate glycemic regulation in children and adolescents transitioning from MDI to in-sulin pumps and to raise awareness among patients and their families regarding the benefits of these systems. Methods: 50 pediatric patients with T1DM (24 males, 26 fe-males; mean age 10.76 ± 3.2 years) were evaluated. Cycle 1 established MDI metrics 3 months pre-transition. In cycle 2, patients transitioned either to an AID system (Medtronic MiniMed 780G, 78%), or a non-automated system (Omnipod DASH, 22%). Data were assessed at 3- and 6-months post-initiation. Parameters assessed were: Glycosylated hemoglobin (HbA1c), Time In Range (TIR), Time Above Range (TAR), Time Below Range (TBR), Glucose Management Indicator (GMI), Coefficient of Variation (CV). Results: The cohort exhibited a statistically significant increase in TIR (p=0.0038) with mean values of 70.9% at 3 months and 70.8% at 6 months. TAR significantly reduced (p=0.033) to 26.5% and 24.3% at 3 and 6 months, respectively. Sub-analysis in the AID group, revealed a marked increase in TIR (p=0.0001) alongside significant reductions in TAR (P=0.0009) and GMI (p=0.03). Conclusion: Transitioning from MDI to insulin pump therapy, particularly AID systems, is transforming the clinical landscape of T1DM management. The con-sistency of these results across age groups indicates that AID systems can successfully overcome pediatric and adolescent diabetes management challenges.
- Open Access
Disordered Eating Behaviors in Children and Adolescents with Type 1 Diabetes: Age-Specific Challenges and Management Insights
Type 1 diabetes is the most common autoimmune endocrine disorder in children and adolescents, with incidence rising worldwide. Its management demands comprehensive care encompassing glucose monitoring, insulin therapy, and individualized nutritional education to support glycemic control and overall health. Establishing normal eating patterns is pivotal not only for prandial euglycemia but also for reducing the risk of disordered eating behaviors and eating disorders that are more frequently observed in youth with diabetes. Because eating patterns and self-management capabilities vary by developmental stage, interventions must be tailored to the physical, psychological, and social context of each age group. Screening tools such as the Diabetes Eating Problem Survey—Revised (DEPS-R) enable timely identification of at-risk individuals. In this scoping review we present the data from the literature regarding the eating patterns and deviations from infancy to adolescence, report the complications and discuss the challenges and insights for their management.
Open AccessDisordered Eating Behaviors in Children and Adolescents with Type 1 Diabetes: Age-Specific Challenges and Management Insights
Type 1 diabetes is the most common autoimmune endocrine disorder in children and adolescents, with incidence rising worldwide. Its management demands comprehensive care encompassing glucose monitoring, insulin therapy, and individualized nutritional education to support glycemic control and overall health. Establishing normal eating patterns is pivotal not only for prandial euglycemia but also for reducing the risk of disordered eating behaviors and eating disorders that are more frequently observed in youth with diabetes. Because eating patterns and self-management capabilities vary by developmental stage, interventions must be tailored to the physical, psychological, and social context of each age group. Screening tools such as the Diabetes Eating Problem Survey—Revised (DEPS-R) enable timely identification of at-risk individuals. In this scoping review we present the data from the literature regarding the eating patterns and deviations from infancy to adolescence, report the complications and discuss the challenges and insights for their management.
- Open Access
Association of Fetal Growth Retardation with Postnatal Osteoprotegerin Concentrations and Aortic Intima–Media Thickness
Background: Fetal Growth Retardation (FGR) is considered a risk factor for atherosclerosis and coronary artery disease in adulthood. Osteoprotegerin (OPG), a member of the tumor necrosis factor receptor superfamily, is reported to be elevated in atherosclerosis. Objectives: In this case-control study, we investigated whether FGR affects postnatal OPG serum concentrations and the possible association between OPG levels and aortic intima–media thickness (aIMT), an index of preclinical atherosclerosis. Methods: We studied 30 infants with FGR and 30 appropriate for gestational age (AGA) infants matched for gestational age and sex. Quantitative determination of plasma OPG was performed via enzyme immunoassay on the second (DOL2) and fifth (DOL5) day of life. aIMT was measured in the distal abdominal aorta and adjusted for aortic lumen diameter. Results: Infants with FGR had significantly higher OPG levels on both DOL2 and DOL5 as compared to controls (DOL2: 5.4 ± 1.0 pmol/L vs. 4.6 ± 1.0 pmol/L, p = 0.002 and DOL5: 5.1 ± 0.8 pmol/L vs. 3.9 ± 0.7 pmol/L, p < 0.001). Between DOL2 and DOL5, OPG concentrations did not change significantly in infants with FGR (difference 0.3 ± 0.2 pmol/L, p = 0.087) but decreased slightly in controls (difference 0.7 ± 0.3 pmol/L, p = 0.003). FGR was also associated with increased aIMT (0.11 ± 0.03 vs. 0.06 ± 0.02, p < 0.001). There was a positive correlation between OPG and aIMT on DOL2 (r = 0.494, p < 0.001), which became stronger on DOL5 (r = 0.791, p < 0.001). Conclusions: We report significantly increased concentrations of OPG in infants with FGR and a positive correlation with aIMT. Follow-up studies with repeat OPG and aIMT measurements may be indicated to evaluate whether these findings represent a permanent effect of FGR on the offspring.
Open AccessAssociation of Fetal Growth Retardation with Postnatal Osteoprotegerin Concentrations and Aortic Intima–Media Thickness
Background: Fetal Growth Retardation (FGR) is considered a risk factor for atherosclerosis and coronary artery disease in adulthood. Osteoprotegerin (OPG), a member of the tumor necrosis factor receptor superfamily, is reported to be elevated in atherosclerosis. Objectives: In this case-control study, we investigated whether FGR affects postnatal OPG serum concentrations and the possible association between OPG levels and aortic intima–media thickness (aIMT), an index of preclinical atherosclerosis. Methods: We studied 30 infants with FGR and 30 appropriate for gestational age (AGA) infants matched for gestational age and sex. Quantitative determination of plasma OPG was performed via enzyme immunoassay on the second (DOL2) and fifth (DOL5) day of life. aIMT was measured in the distal abdominal aorta and adjusted for aortic lumen diameter. Results: Infants with FGR had significantly higher OPG levels on both DOL2 and DOL5 as compared to controls (DOL2: 5.4 ± 1.0 pmol/L vs. 4.6 ± 1.0 pmol/L, p = 0.002 and DOL5: 5.1 ± 0.8 pmol/L vs. 3.9 ± 0.7 pmol/L, p < 0.001). Between DOL2 and DOL5, OPG concentrations did not change significantly in infants with FGR (difference 0.3 ± 0.2 pmol/L, p = 0.087) but decreased slightly in controls (difference 0.7 ± 0.3 pmol/L, p = 0.003). FGR was also associated with increased aIMT (0.11 ± 0.03 vs. 0.06 ± 0.02, p < 0.001). There was a positive correlation between OPG and aIMT on DOL2 (r = 0.494, p < 0.001), which became stronger on DOL5 (r = 0.791, p < 0.001). Conclusions: We report significantly increased concentrations of OPG in infants with FGR and a positive correlation with aIMT. Follow-up studies with repeat OPG and aIMT measurements may be indicated to evaluate whether these findings represent a permanent effect of FGR on the offspring.
- 24 October 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (1) , e182-e191
Molecular Analysis of the CYP11B2 Gene in 62 Patients with Hypoaldosteronism Due to Aldosterone Synthase Deficiency
Context: Isolated congenital hypoaldosteronism presents in early infancy with symptoms including vomiting, severe dehydration, salt wasting, and failure to thrive. The main causes of this rare autosomal recessive disorder is pathogenic variants of the CYP11B2 gene leading to aldosterone synthase deficiency. Objective: To investigate the presence of CYP11B2 pathogenic variants in a cohort of patients with a clinical, biochemical, and hormonal profile suggestive of aldosterone synthase deficiency. Design: Clinical and molecular study. Setting: Tertiary academic Children’s Hospital, Center for Rare Pediatric Endocrine Diseases. Patients and Methods: Sixty-two patients (56 unrelated patients and 6 siblings), with hypoaldosteronism and their parents, underwent CYP11B2 gene sequencing after its selective amplification against the highly homologous CYP11B1 gene. In silico analysis of the identified novel variants was carried out to evaluate protein stability and potential pathogenicity. Results: CYP11B2 gene sequencing revealed that 62 patients carried a total of 12 different pathogenic CYP11B2 gene variants, 6 of which are novel. Importantly, 96% of the 56 patients carried the previously reported p.T185I variant either in homozygosity or in compound heterozygosity with another variant. The 6 novel variants detected were: p.M1I, p.V129M, p.R141Q, p.A165T, p.R448C, and the donor splice site variant of intron 8, c.1398 + 1G > A. Conclusion: Molecular diagnosis was achieved in 62 patients with aldosterone synthase deficiency, the largest cohort thus far reported. Six novel genetic variants were identified as possibly pathogenic, extending the spectrum of reported molecular defects of the CYP11B2 gene.
- 24 October 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (1) , e182-e191
Molecular Analysis of the CYP11B2 Gene in 62 Patients with Hypoaldosteronism Due to Aldosterone Synthase Deficiency
Context: Isolated congenital hypoaldosteronism presents in early infancy with symptoms including vomiting, severe dehydration, salt wasting, and failure to thrive. The main causes of this rare autosomal recessive disorder is pathogenic variants of the CYP11B2 gene leading to aldosterone synthase deficiency. Objective: To investigate the presence of CYP11B2 pathogenic variants in a cohort of patients with a clinical, biochemical, and hormonal profile suggestive of aldosterone synthase deficiency. Design: Clinical and molecular study. Setting: Tertiary academic Children’s Hospital, Center for Rare Pediatric Endocrine Diseases. Patients and Methods: Sixty-two patients (56 unrelated patients and 6 siblings), with hypoaldosteronism and their parents, underwent CYP11B2 gene sequencing after its selective amplification against the highly homologous CYP11B1 gene. In silico analysis of the identified novel variants was carried out to evaluate protein stability and potential pathogenicity. Results: CYP11B2 gene sequencing revealed that 62 patients carried a total of 12 different pathogenic CYP11B2 gene variants, 6 of which are novel. Importantly, 96% of the 56 patients carried the previously reported p.T185I variant either in homozygosity or in compound heterozygosity with another variant. The 6 novel variants detected were: p.M1I, p.V129M, p.R141Q, p.A165T, p.R448C, and the donor splice site variant of intron 8, c.1398 + 1G > A. Conclusion: Molecular diagnosis was achieved in 62 patients with aldosterone synthase deficiency, the largest cohort thus far reported. Six novel genetic variants were identified as possibly pathogenic, extending the spectrum of reported molecular defects of the CYP11B2 gene.
- 1 April 2016
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 174 (4) , 473-479
The effect of GH treatment on serum FGF23 and Klotho in GH-deficient children
Background: Normal phosphate homeostasis is essential for normal linear growth. The phosphaturic fibroblast growth factor 23 (FGF23)/Klotho axis is a major regulator of phosphate homeostasis; therefore, an intact FGF23/Klotho axis is important for normal linear growth. On the other hand, GH/IGF1 axis has opposing effects on phosphate homeostasis, but the underline mechanisms remain unclear.Aim: The main objective of this study was to investigate the possible interactions of FGF23 and its co-receptor Klotho, with growth hormone (GH)/IGF1 axis in the regulation of phosphate metabolism in GH-deficient children under GH treatment.Methods: We studied 23 GH-deficient children, before and 3 months after the onset of GH treatment. Anthropometry and assessment of biochemical parameters were performed, as well as measurement of FGF23 (intact FGF23/iFGF23 and C-terminal FGF23/cFGF23) and soluble α-Klotho (sKlotho) levels.Results: After 3 months on GH treatment, the elevation of serum phosphate and TmPO4/GFR (PPPPPPPPPPPPPPP<0.001).Conclusion: The increase in serum phosphate, which we found in GH-deficient children under GH treatment, is not associated with suppression but rather than with upregulation of the phosphaturic FGF23/Klotho axis.
- 1 April 2016
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 174 (4) , 473-479
The effect of GH treatment on serum FGF23 and Klotho in GH-deficient children
Background: Normal phosphate homeostasis is essential for normal linear growth. The phosphaturic fibroblast growth factor 23 (FGF23)/Klotho axis is a major regulator of phosphate homeostasis; therefore, an intact FGF23/Klotho axis is important for normal linear growth. On the other hand, GH/IGF1 axis has opposing effects on phosphate homeostasis, but the underline mechanisms remain unclear.Aim: The main objective of this study was to investigate the possible interactions of FGF23 and its co-receptor Klotho, with growth hormone (GH)/IGF1 axis in the regulation of phosphate metabolism in GH-deficient children under GH treatment.Methods: We studied 23 GH-deficient children, before and 3 months after the onset of GH treatment. Anthropometry and assessment of biochemical parameters were performed, as well as measurement of FGF23 (intact FGF23/iFGF23 and C-terminal FGF23/cFGF23) and soluble α-Klotho (sKlotho) levels.Results: After 3 months on GH treatment, the elevation of serum phosphate and TmPO4/GFR (PPPPPPPPPPPPPPP<0.001).Conclusion: The increase in serum phosphate, which we found in GH-deficient children under GH treatment, is not associated with suppression but rather than with upregulation of the phosphaturic FGF23/Klotho axis.
- 1 October 2012
- Published by Springer Nature in Hormones
- Vol. 11 (4) , 501-504
45,X/46,XY mosaicism: a cause of short stature in males
45,X/46,XY mosaicism is associated with a broad spectrum of phenotypes ranging from apparently normal male development to individuals with incomplete sexual differentiation and clinical signs of Turner syndrome in both males and females. The most common presentation among individuals with a 45,X/46,XY karyotype is sexual ambiguity, accounting for approximately 60% of cases, while the least common category of 45,X/46,XY patients consists of those with bilaterally descended testes, found in 11-12%. We report on two patients with an apparently normal male phenotype and 45,X/46,XY mosaicism who were diagnosed postnatally because of short stature. Both of these boys presented at the age of 15 years with short stature, minor Turner-like stigmata, normal male external genitalia and spontaneous pubertal development. One of them had coarctaction of the aorta with bicuspid aortic valve, an uncommon clinical feature in boys with mosaicism. The same patient underwent a trial of GH replacement therapy with poor response and his sperm analysis revealed azoospermia. Like our patients, most mosaic 45,X/46,XY children with bilateral scrotal testes go unrecognised at birth and throughout childhood unless they have somatic features of Turner syndrome or significant growth retardation. We recommend that boys with otherwise unexplained short stature, being short for their families, should be karyotyped routinely as is recommended in short-stature girls. In addition, boys with 45,X/46,XY mosaicism require a thorough clinical evaluation similar to that performed in girls with Turner syndrome and must be routinely followed up for their potential to respond favorably to GH treatment and for late onset abnormalities, such as infertility and gonadal tumors.
- 1 October 2012
- Published by Springer Nature in Hormones
- Vol. 11 (4) , 501-504
45,X/46,XY mosaicism: a cause of short stature in males
45,X/46,XY mosaicism is associated with a broad spectrum of phenotypes ranging from apparently normal male development to individuals with incomplete sexual differentiation and clinical signs of Turner syndrome in both males and females. The most common presentation among individuals with a 45,X/46,XY karyotype is sexual ambiguity, accounting for approximately 60% of cases, while the least common category of 45,X/46,XY patients consists of those with bilaterally descended testes, found in 11-12%. We report on two patients with an apparently normal male phenotype and 45,X/46,XY mosaicism who were diagnosed postnatally because of short stature. Both of these boys presented at the age of 15 years with short stature, minor Turner-like stigmata, normal male external genitalia and spontaneous pubertal development. One of them had coarctaction of the aorta with bicuspid aortic valve, an uncommon clinical feature in boys with mosaicism. The same patient underwent a trial of GH replacement therapy with poor response and his sperm analysis revealed azoospermia. Like our patients, most mosaic 45,X/46,XY children with bilateral scrotal testes go unrecognised at birth and throughout childhood unless they have somatic features of Turner syndrome or significant growth retardation. We recommend that boys with otherwise unexplained short stature, being short for their families, should be karyotyped routinely as is recommended in short-stature girls. In addition, boys with 45,X/46,XY mosaicism require a thorough clinical evaluation similar to that performed in girls with Turner syndrome and must be routinely followed up for their potential to respond favorably to GH treatment and for late onset abnormalities, such as infertility and gonadal tumors.